TT-P34
Parkinson's Disease
Key Facts
About Teitur Trophics
Teitur Trophics is a private, clinical-stage biotech based in Copenhagen, Denmark, advancing novel therapeutics for neurodegenerative disorders. The company's core technology is a platform of cyclic peptides designed to address fundamental pathological hallmarks, with its lead program TT-P34 now in Phase I clinical trials for Parkinson's disease. Teitur operates as a pre-revenue therapeutics company, having spun out from Aarhus University, and is focused on achieving proof-of-concept in humans to validate its unique mechanism of action. The initiation of patient dosing marks a critical transition from preclinical research to clinical development.
View full company profileAbout Teitur Trophics
Teitur Trophics is a private, clinical-stage biotech based in Copenhagen, Denmark, advancing novel therapeutics for neurodegenerative disorders. The company's core technology is a platform of cyclic peptides designed to address fundamental pathological hallmarks, with its lead program TT-P34 now in Phase I clinical trials for Parkinson's disease. Teitur operates as a pre-revenue therapeutics company, having spun out from Aarhus University, and is focused on achieving proof-of-concept in humans to validate its unique mechanism of action. The initiation of patient dosing marks a critical transition from preclinical research to clinical development.
View full company profileAbout Teitur Trophics
Teitur Trophics is a private, clinical-stage biotech based in Copenhagen, Denmark, advancing novel therapeutics for neurodegenerative disorders. The company's core technology is a platform of cyclic peptides designed to address fundamental pathological hallmarks, with its lead program TT-P34 now in Phase I clinical trials for Parkinson's disease. Teitur operates as a pre-revenue therapeutics company, having spun out from Aarhus University, and is focused on achieving proof-of-concept in humans to validate its unique mechanism of action. The initiation of patient dosing marks a critical transition from preclinical research to clinical development.
View full company profileTherapeutic Areas
Other Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT200-11 | Neuropore Therapies | Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| VXX-301 | Vaxxinity | Preclinical |
| BAN2802 | BioArctic | Phase 1 |
| CNM-Au8 | Clene | Phase 2 |
| hpSC-Derived Neural/Dopaminergic Cells | International Stem Cell | Preclinical/Early Clinical |
| SLS-004 | Seelos Therapeutics | Preclinical |
| SLS-007 | Seelos Therapeutics | Preclinical |
| Parkinson's Disease Portfolio (Platform-derived) | WD Pharmaceutical | Not Disclosed (Likely Preclinical/Early Clinical) |
| UX-DA001 | UniXell | Phase 1 |
| Parkinson's Disease Research | ProgenaBiome | Research |
| A9 Dopaminergic Neuron Therapy | Trailhead Biosystems | Pre-clinical |